Xilio Therapeutics (XLO) Operating Expenses (2020 - 2026)

Xilio Therapeutics (XLO) has 7 years of Operating Expenses data on file, last reported at $26.8 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 59.47% year-over-year to $26.8 million; the trailing twelve-month figure through Mar 2026 stood at $95.7 million (up 44.56% YoY), and the FY2025 full-year result was $85.7 million, up 28.12% from the prior year.
• Operating Expenses climbed to $26.8 million in Q1 2026, from $25.5 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $26.8 million in Q1 2026 to a low of $15.4 million in Q4 2024.
• A 5-year average of $20.5 million and a median of $20.2 million in 2022 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses decreased 25.67% in 2024 and soared 66.23% in 2025, its largest moves.
• Tracing XLO's Operating Expenses over 5 years: stood at $23.2 million in 2022, then retreated by 21.74% to $18.1 million in 2023, then fell by 15.32% to $15.4 million in 2024, then soared by 66.23% to $25.5 million in 2025, then climbed by 4.85% to $26.8 million in 2026.
• Business Quant data shows XLO's Operating Expenses at $26.8 million in Q1 2026, $25.5 million in Q4 2025, and $21.0 million in Q3 2025.